SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
Turnover
51.02%
1-Year Est. Return
524.65%
This Fund
S&P 500
This Quarter
Est. Return
+7.72%
1 Year Est. Return
+524.65%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.09%
10 Year Est. Return
–
AUM
$247M
AUM Growth
+$69.9M
(+40%)
Cap. Flow
+$48.7M
Cap. Flow
% of AUM
19.75%
Top 10 Holdings %
Top 10 Hldgs %
43.11%
Holding
96
New
14
Increased
43
Reduced
12
Closed
25
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$6.72M |
| 2 |
APEN
Apollo Endosurgery, Inc.
APEN
|
+$6.46M |
| 3 |
Immunogen Inc
IMGN
|
+$5.37M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
+$4.88M |
| 5 |
BridgeBio Pharma
BBIO
|
+$4.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fulcrum Therapeutics
FULC
|
+$5.24M |
| 2 |
NextCure
NXTC
|
+$3.68M |
| 3 |
Arvinas
ARVN
|
+$3.06M |
| 4 |
Insmed
INSM
|
+$2.11M |
| 5 |
Erasca
ERAS
|
+$1.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.66% |
| 2 | Miscellaneous | 9.6% |
| 3 | Financials | 5.02% |
| 4 | Industrials | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.71B
| $22.4M | 9.07% |
+200,000
| New | +$24.1M |
2021 Q4
0 quarters
|
|
|
2
DELISTED
Immunogen Inc
IMGN
| $11.2M | 4.55% |
1,514,411
+864,492
| +133% | +$5.37M |
2020 Q4
4 quarters
|
|
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $11.1M | 4.49% |
80,348
+18,451
| +30% | +$2.35M |
2020 Q4
4 quarters
|
|
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.2M | 4.14% |
195,000
+93,110
| +91% | +$3.91M |
2020 Q4
4 quarters
|
|
5
DELISTED
Merus
MRUS
| $10.2M | 4.13% |
320,174
-25,790
| -7% | -$729K |
2021 Q1
3 quarters
|
|
6
Veracyte
VCYT
$3.49B
| $9.12M | 3.7% |
221,362
+41,814
| +23% | +$1.85M |
2021 Q1
3 quarters
|
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.91M | 3.61% |
60,757
+14,816
| +32% | +$2.3M |
2020 Q4
4 quarters
|
|
|
BLU
8
DELISTED
BELLUS Health Inc.
BLU
| $8.86M | 3.59% |
1,100,000
+735,000
| +201% | +$4.88M |
2021 Q2
2 quarters
|
|
9
Cogent Biosciences
COGT
$4.85B
| $7.3M | 2.96% |
850,935
+173,035
| +26% | +$1.5M |
2020 Q4
4 quarters
|
|
|
10
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.92B
| $7.11M | 2.88% |
+128,901
| New | +$6.72M |
2021 Q4
0 quarters
|
|
11
Cerus
CERS
$449M
| $7.1M | 2.88% |
1,042,722
+423,353
| +68% | +$2.85M |
2021 Q2
2 quarters
|
|
|
HZNP
12
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.65M | 2.69% |
61,700
+9,231
| +18% | +$1.01M |
2020 Q4
4 quarters
|
|
13
DELISTED
iTeos Therapeutics
ITOS
| $6.43M | 2.6% |
138,006
+21,075
| +18% | +$702K |
2021 Q2
2 quarters
|
|
|
APEN
14
DELISTED
Apollo Endosurgery, Inc.
APEN
| $6.24M | 2.53% |
+739,604
| New | +$6.46M |
2021 Q4
0 quarters
|
|
|
RACB
15
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $5.42M | 2.19% |
556,890
+83,494
| +18% | +$821K |
2021 Q1
3 quarters
|
|
16
Immatics
IMTX
$1.05B
| $5.26M | 2.13% |
391,155
-46,711
| -11% | -$584K |
2021 Q1
3 quarters
|
|
|
LHDX
17
DELISTED
Lucira Health, Inc. Common Stock
LHDX
| $4.43M | 1.8% |
515,000
+294,242
| +133% | +$1.87M |
2021 Q3
1 quarter
|
|
|
SRRA
18
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $4.17M | 1.69% |
192,045
+28,559
| +17% | +$629K |
2020 Q4
4 quarters
|
|
19
Aclaris Therapeutics
ACRS
$496M
| $4.16M | 1.69% |
286,226
+112,899
| +65% | +$1.71M |
2021 Q1
3 quarters
|
|
|
AMYT
20
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $3.78M | 1.53% |
350,213
-166,008
| -32% | -$1.79M |
2020 Q4
4 quarters
|
|
|
CTIC
21
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $3.68M | 1.49% |
+1,483,829
| New | +$3.63M |
2021 Q4
0 quarters
|
|
22
Cypherpunk Technologies Inc
CYPH
$280M
| $3.28M | 1.33% |
101,366
+39,366
| +63% | +$1.09M |
2021 Q3
1 quarter
|
|
23
Krystal Biotech
KRYS
$9.73B
| $3.27M | 1.32% |
+46,670
| New | +$2.72M |
2021 Q4
0 quarters
|
|
24
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.19M | 1.29% |
67,440
+9,736
| +17% | +$522K |
2020 Q4
4 quarters
|
|
25
DELISTED
Crinetics Pharmaceuticals
CRNX
| $3.18M | 1.29% |
111,860
+62,478
| +127% | +$1.54M |
2021 Q3
1 quarter
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Silverarc Capital Management held 96 positions worth $247M, up 40% from $177M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Silverarc Capital Management deployed $48.7M of net new capital in Q4 2021, opening 14 new positions and adding to 43 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was NextCure, an estimated $3.68M trimmed.
- Silverarc Capital Management's largest Q4 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 128,901 shares worth $7.11M.
- Silverarc Capital Management added most to Immunogen Inc in Q4 2021, an estimated $5.37M increase.
- Silverarc Capital Management's biggest Q4 2021 reduction was NextCure, cutting an estimated $3.68M.
- Silverarc Capital Management fully exited Fulcrum Therapeutics in Q4 2021, selling an estimated $5.24M.
- Silverarc Capital Management's ten largest holdings make up 43% of its $247M portfolio in Q4 2021.
- Silverarc Capital Management opened 14 new positions and closed 25 in Q4 2021.
- Silverarc Capital Management's portfolio value rose 40% quarter-over-quarter to $247M.
Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.